My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

206.60 -4.72 (-2.23%)

Official Closing Price Updated: 7:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

97 98 Next >

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗

Today 8:45 EDT

Via MarketBeat

MarketBeat Week in Review – 04/27 - 05/01 ↗

Today 7:00 EDT

Via MarketBeat

Aqua Medical Spa Launches New Website to Showcase Aesthetic and Wellness Services in London, ON

May 01, 2026

Via GetFeatured

ABBV Q1 Deep Dive: Immunology and Neuroscience Growth, Raised Full-Year Outlook

April 30, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.8% year on year to $13.98 billion. Its non-G...

Via StockStory

AbbVie Inc (NYSE:ABBV) Beats Q1 Estimates and Raises Full-Year Profit Guidance ↗

April 29, 2026

Via Chartmill

EDMP picks up Sonoco, and the position size is doing the talking ↗

April 29, 2026

Sonoco Products Company delivers packaging solutions to global consumer and industrial markets, with a reported dividend yield of 4.2%.

Via The Motley Fool

Topics Regulatory Compliance

AbbVie (ABBV) Stock Trades Up, Here Is Why

April 29, 2026

What Happened? Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.5% in the afternoon session after the company reported first-quarter results that...

Via StockStory

Topics Artificial Intelligence Earnings World Trade

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead? ↗

April 29, 2026

Via MarketBeat

AbbVie (ABBV) Q1 2026 Earnings Transcript ↗

April 29, 2026

AbbVie (ABBV) Q1 2026 Earnings Transcript

Via The Motley Fool

AbbVie’s (NYSE:ABBV) Q1 CY2026 Sales Top Estimates

April 29, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q1 CY2026, with sales up 12.4% year on year to $15 billion. Its non-GAAP ...

Via StockStory

Should You Buy AbbVie Stock Hand Over Fist Before April 29? ↗

April 28, 2026

Mind your investment horizon.

Via The Motley Fool

Topics Intellectual Property

AbbVie (ABBV) To Report Earnings Tomorrow: Here Is What To Expect

April 27, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Wednesday before market hours. Here’s what to expect. AbbVie beat analysts...

Via StockStory

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4

April 22, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stoc...

Via StockStory

Topics Artificial Intelligence

Should You Forget Pfizer and Buy This Pharma Stock Instead? ↗

April 22, 2026

Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?

Via The Motley Fool

Topics Intellectual Property

Growth in Non-Surgical Aesthetic Treatments Reported Across Tampa Bay Locations

April 21, 2026

Via Press Release Distribution Service

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗

April 21, 2026

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Via The Motley Fool

The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond ↗

April 19, 2026

These stocks pay juicy dividends but also offer much more.

Via The Motley Fool

Topics Economy

3 Stocks I Plan to Hold for the Next 20 Years ↗

April 18, 2026

These stocks are keepers.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

The Psychedelic Revolution in Mental Healthcare ↗

April 17, 2026

Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and...

Via The Motley Fool

Why AbbVie Is a No-Brainer Stock to Buy on the Dip ↗

April 16, 2026

The pharma giant is still a rock-solid dividend stock.

Via The Motley Fool

1 Value Stock Worth Your Attention and 2 That Underwhelm

April 16, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the Market ↗

April 15, 2026

These stocks pay between 3.3% and 6.3% and are backed by strong financials.

Via The Motley Fool

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

This Indicator Has Called Every Recession Over the Last 80 Years. Here's What It's Saying Now. ↗

April 14, 2026

The U.S. economy could be starting a vicious cycle if this indicator is right.

Via The Motley Fool

Topics Economy

2 S&P 500 Stocks with Solid Fundamentals and 1 We Brush Off

April 14, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Via StockStory

Topics Stocks

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Topics Earnings Economy Intellectual Property

S&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend. ↗

April 13, 2026

There are still some generous yielders if you know where to look.

Via The Motley Fool

Topics Stocks

3 Market-Beating Stocks with Competitive Advantages

April 10, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

97 98 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.